Maxcyte Inc

0.00 (0.0%)
Share Name Share Symbol Market Type Share ISIN Share Description
Maxcyte Inc LSE:MXCT London Ordinary Share COM STK USD0.01 (DI)
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 350.00 1,666 08:00:00
Bid Price Offer Price High Price Low Price Open Price
340.00 360.00 350.00 350.00 350.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Biological Pds,ex Diagnstics 44.26 -23.57 -23.00 - 360.68
Last Trade Time Trade Type Trade Size Trade Price Currency
12:33:38 O 464 348.00 GBX

Maxcyte (MXCT) Latest News

Maxcyte (MXCT) Discussions and Chat

Maxcyte Forums and Chat

Date Time Title Posts
03/6/202310:13Maxcyte: Any molecule, any cell, any scale1,363
21/1/202214:00Anybody know what is going on?-
13/7/202112:48MaxCyte (MXCT) Right here, right now: catching the CAR-T wave5

Add a New Thread

Maxcyte (MXCT) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2023-06-08 11:33:38348.004641,614.72O
2023-06-08 10:30:53348.003361,169.28O
2023-06-08 09:03:59348.00827.84O
2023-06-08 08:29:58355.008463,003.30O
2023-06-08 07:39:45360.0013.60O

Maxcyte (MXCT) Top Chat Posts

Top Posts
Posted at 01/6/2023 15:36 by epicwarlock
Where's the love for MXCT? Anyone clued in on any newsflow which may get this moving one way or another?
Posted at 10/5/2023 21:20 by adamb1978
Dogs dinner of results. Trying to find something positive in them....struggling....though I guess that given expectations had seemed to be spectacularly reduced, these figures are in-line.

Other consolation is that this is a long term story rather than something short-term, so if 1 year is only marginally up, then you lose 1 years cost of money rather than the company having retreated

In terms of share price performance, things which might hold it up are:

(i) Share price having already been marked down as a result of the reduced guidance (results were in-line after all)
(ii) Positive CRISPR/exa-cel news from recent weeks

Most frustrating thing is that the 2023 guidance was only issued 2 months ago (15th March) so its a significant reduction in a short period

Posted at 08/5/2023 23:04 by rgmgo
The estimates are at a group level ie including an SPL contribution. They are not my numbers, so I'm not going to make any claims about their veracity. We know that one customer, presumably CRISPR, accounted for just shy of a quarter of revenue last year, so if I were trying to rationalise such a low 1Q sales figure I would guess the largest customer revenues fell precipitously & SPL revenues were also sharply lower. Working on the basis of anticipated exa-cel approval you can also rationalise the sharp rebound in the balance of the year as presumably commercialisation will require higher volumes than seen in the pivotal trial. I would argue that you can make an investment case for MXCT even in the absence of exa-cel approval (but that would move the growth curve materially to the right with associated short term share price implications). MXCT is far from a one product company but exa-cel undoubtedly plays a disproportionate role in 2023.It is also possible that The Street has been steered to a low number to achieve a material beat. My guess is that 1Q will be weak, but that is based on gut feel rather than analysis as I don't think there is enough info in the public domain to precisely forecast the quarter. As mentioned before, we will know soon enough.
Posted at 27/4/2023 17:14 by epicwarlock
Thank you Adam,I'm of a similar view and actually doubled down on my position today, making it the largest investment/ punt in my SIPP today next to 888.LSee this as a worthwhile 5-10yr holding with a realistic chance of 5-baggging or more if MXCT can deliver successfully on their pipeline.(Have to withdraw & apologize for my comments on recent share price volatility...when I wrote my previous post I'd just finished reviewing a presentation for TUNE, which had lost ~20% over 2 days, so I had those numbers in mind, rather than MXCT. I swear I've had "brain fog" ever since C19 lockdown ?)GLA
Posted at 27/4/2023 08:59 by adamb1978
Hi Epic

I generally wouldnt worry about day to day fluctuations in MXCT's share price...or put another way, if the day to day fluctuations make you uncomfortable, then perhaps worth considering whether this is the right investment for you.

Personally I take a 3-5 year, or longer, view on this one and quite sanguine about shorter term movements and trying to guess might caused it. I'm not in this to make 30% or 50% - more like 5x, 10x or 20x (from current levels).

Nearer term than that, I think we'll see approval for exa-cel come through late this year, a handful more SPLs, turnover grinding higher by another 25%-35% and some flatlining in the cost base. On top of that, news of another FDA submission by one of its customers would be great or the various other blue-birds


Posted at 28/3/2023 19:00 by adamb1978
Hi Elsa - welcome. MXCT is one of my holdings for the long-term which I think has a viable chance of 10-bagging or more. 2023 could be a big year for MXCT with the Vertex approval from the FDA possibly coming in Q4. And in the meantime they continue to build the pipeline of SPLs which pay the annual licence fees and build up that recurring base.

Expect volatility, but these are swimming in cash which limits the downside


Posted at 22/3/2023 11:10 by adamb1978
Option awards look fine given the vesting price = the market price

If the share price doubles, DD would make $1.6m from the options. I certainly wouldnt begrudge him that if he achieves that doubling!

Posted at 16/3/2023 19:59 by thetrotsky
Hi Supernumerary,

Accounts receivable have actually gone up by about $4.8m. I suspect that this is in part due to the timing of the $1.85m program-related income milestone in Q4 and the general income increase in FY22 compared to FY21. Nevertheless, assuming that the Q4 program-related income was outstanding at the end of FY22, debtor days appear to have increased from c61 days to c83 days (based on Q4 income). Not a total disaster but, as you imply, suggestive that customers are stretching their credit as their ability to raise new funds becomes more difficult. Ultimately they are going to have to pay or MXCT can (literally) shut them down by stopping supply of the bespoke reagents they need to undertake their research. There is undoubtedly a heightend risk that some customers might fail but nothing abnormal IMHO for this stage in the economic cycle.

I think the accounts receivable increase that you have alighted upon are the TIA accounts receivable. I believe, but stand to be corrected, that these may relate amounts receivable from MXCT's landlord(s) for property improvements incurred by MXCT which would, in the normal course of business, be offsetable against future rental payments over the period of their initial lease.


Posted at 16/3/2023 10:58 by trident5
Yeah - if it doesn't become profitable the share price will head to zero.
Posted at 15/3/2023 09:33 by adamb1978
Results are this evening, though we already know the 2022 top line figure and their initial guidance for 2023.

MXCT share price has been weak recently however if you look at various other healthcare companies, most of them have come off too.

Maxcyte share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

Log in to ADVFN
Register Now

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |

V: D: 20230609 02:28:50